Nevada Copper Corp (TSX:NCU, OTC:NEVDF) has released updates on its plans to restart activities at its Pumpkin Hollow underground copper mine and on its previously-announced financing package which is expected to provide up to $93 million to support the development of the mine. "We have made significant progress in developing the plans, recruiting the people and implementing the systems necessary to derisk the restart,” Randy Buffington, president and CEO, said in a statement. “We believe that taking a careful, phased approach to restarting the mine removes some of the bottlenecks the operation has faced in the past and will facilitate a rapid ramp-up to nameplate capacity once the mill restarts in mid-2023.”
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) has announced an exclusive licensing agreement for Cybin Inc to acquire intellectual property rights for a subset of Mindset's preclinical compounds. Under the terms of the agreement, biopharmaceutical company Cybin will license intellectual property related to preclinical compounds within Mindset's Family 1 portfolio, excluding MSP-1014, Mindset's lead psychedelic drug candidate. Mindset Pharma CEO James Lanthier said that over the past two years, Cybin has assembled a leading psychedelic drug development organization.
EverGen Infrastructure Corp (TSX-V:EVGN) said its wholly owned subsidiary Fraser Valley Biogas Ltd. has signed a term sheet for a long-term offtake agreement. The agreement is expected to cover the purchase of up to 190,000 gigajoules (GJ) of RNG (renewable natural gas) annually from Fraser Valley which accounts for existing and incremental RNG volumes expected from the facility after the completion of EverGen’s Core RNG expansion project. "This marks another key milestone for EverGen and underpins our expansion at Fraser Valley Biogas," Chase Edgelow, CEO of EverGen said in a statement. "Our Core RNG expansion projects are fully funded to deliver RNG production of nearly half a million GJ annually, using a solution that captures greenhouse gases to supply low-carbon energy, supporting the energy transition."
Psyched Wellness Ltd (CSE:PSYC, OTCQB:PSYCF) said it has received positive feedback from test subjects who participated in the pilot run of 300 bottles of Calm, the first legal Amanita Muscaria extract available for sale in the US. The feedback provided the necessary information to determine the final flavour formulation for Calm, the company said, adding that pre-orders are now sold out and shipping will commence mid to end-October. "We have taken a cautious approach to bringing our flagship product, Calm, to market. We have been working closely with Vantage Hemp, our contract manufacturer and providing them with the feedback from our test participants to ensure we produce the best version of Calm for our consumers," Jeffrey Stevens, CEO of the company said in a statement.
BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) said it has filed a PCT patent application along with a US application for lysergic acid diethylamide (LSD) derivatives, including 2-bromo-LSD. The applications cover compositions of these derivatives for use in the treatment of a range of neuropsychiatric and neurological conditions, including depression, anxiety, cluster headaches and pain, according to BetterLife. BetterLife said it is developing a new composition of 2-bromo-LSD, BETR-001, covered by these patent filings. BETR-001 is a second-generation LSD derivative molecule that does not cause hallucinations, and therefore is not subject to global controlled substance regulations.
Endexx Corp announced that its recently-acquired HYLA division, in which the company has a controlling interest, has secured two major purchase orders for its new innovative vape-delivery product that holds 4,500 puffs per built-in cartridge unit. The developer and distributor of all natural, plant-derived topical skincare products said combined, the orders represent a 150,000-unit order and a 52,000-unit order for over 200,000 units within the first month of the acquisition of Hyla.
Group Eleven Resources Corp (TSX-V:ZNG) has announced plans for follow-up drill programs at the Ballywire and Carrickittle West prospects in Ireland. The company said follow-up drilling at the Ballywire discovery is expected to begin in four to six weeks and finish by year-end. It is planned to consist of an initial five holes totalling 1,500 metres (m), drilled at step-out distances ranging from 100m to 250 m from discovery hole G11-468-03, which returned 66m of mineralization hosting several high-grade zones, including 6.9m of 11.1% zinc, 4.3% lead and 160 grams per ton silver.
Q BioMed Inc said it has received a European Certificate of Grant for GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) licensed from the Washington University in St. Louis, Missouri. Determining the severity of glaucoma using this biomarker will aid in treatment decisions for patients diagnosed with and being treated for glaucoma, according to Q BioMed. Glaucoma is a group of diseases that damage the eye's optic nerve and can result in vision loss and blindness, and is one of the leading causes of blindness worldwide. However, with early detection and treatment, the eyes can be protected against serious vision loss.
NorthWest Copper Corp (TSX-V:NWST) reported additional high-grade drill results as part of a near-surface program at the northern part of the Kwanika deposit located in the prolific Quesnel Terrane, in British Columbia. The Vancouver-based copper-gold explorer noted that this is the third set of drill results reported at Kwanika this year. Results from 15 of 30 holes drilled in 2022 have been reported so far. The company revealed that the set of assays intersected mineralization to the north of the footprint of the Kwanika Central Zone, including high-grade mineralization in hole K-22-234.
Context Therapeutics (NASDAQ:CNTX) Inc has announced a plan to streamline its resources and extend its cash runway into 2024 as market pressures put a strain on biotechnology companies. The women’s oncology company plans to defer noncritical R&D activities, reduce future overhead and infrastructure expenditures and push forward with its onapristone extended release (ONA-XR) ELONA Phase 1b/2 clinical trial and Claudin 6 (CLDN6) program. “In light of the challenging current investment climate for biotechnology, we are streamlining the organization’s resources with the intent to take the company through the execution of the Phase 1b portion of the ELONA trial and the advancement of our CLDN6xCD3 bispecific antibody program to an Investigational New Drug Application (IND),” CEO Martin Lehr said in a statement.
Aion Therapeutic Inc said it expects to file its annual financial statements and management discussion and analysis for the year ended April 30, 2022, together with the related certification of filings under National Instrument 52-109 - Certification of Disclosure in Issuers’ Annual and Interim Filings (Continuous Disclosure Documents), by October 31, 2022. The company said in the event that it fails to do so, the Canadian Securities Regulatory Authorities may impose an issuer cease trade order on the outstanding securities of the company. Until then, Aion said it expects to continue filing the bi-weekly update as required by National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults (NP 12-203). It added that there have been no material changes to the information contained in the Default Announcement it made on August 30, 2022, or any other changes required to be disclosed under NP 12-203.
Universal Ibogaine Inc (TSX-V:IBO) said it was featured in a documentary series entitled ‘Psychedelics Tonight’ on the history and future potential of several psychedelic compounds, including iboga and ibogaine. “We are excited to see a growing variety of media channels pick up the story of ibogaine, to help educate the public, and the medical community, on ibogaine’s potential for use in addiction treatments. We see ibogaine as having a key role in turning the tide on the growing opioid crisis,” said Nick Karos, CEO of Universal Ibogaine. The first episode of the series aired on September 26, 2022, and can be viewed on Apple (NASDAQ:AAPL) TV, Roku and on ALTRD TV.
Jushi Holdings Inc said it has filed its second-quarter ended June 30, 2022 financial statements with the U.S. Securities and Exchange Commission on September 26, 2022. The company has also filed the reviewed and amended Q2 2022 interim financial statements in Canada on SEDAR, replacing those it previously filed on August 29, 2022. In the amended statements, Jushi restated a disclosure pertaining to right of use assets associated with finance leases in the non-cash investing and financing activities section of the statement of cash flows for the comparative six-month period ended June 30, 2021, among certain other revisions made in the course of finalizing the amended statements. The corrections do not have an impact on the net change in cash and cash equivalents and restricted cash during each of the periods presented, it added.
Alkaline Fuel Cell Power Corp (AFCP) said it has filed a management information circular dated September 26, 2022 and related meeting and proxy materials in connection with its upcoming special meeting of shareholders to be held on October 17, 2022, on SEDAR. AFCP will seek shareholder approval to amend the exercise price of certain outstanding common share purchase warrants from between $0.75 and $0.33, which is significantly above current trading prices of the company’s common shares, to $0.20. Additionally, AFCP will seek shareholder approval to amend the exercise price of certain outstanding stock options of the company from between $0.33 and $0.25, also significantly above the current trading price for the common shares, to $0.15. In accordance with the policies of the NEO, warrant holders and option holders who are advantaged by the proposed warrant and option amendments will be excluded from voting. “Since joining AFCP in May of this year, we have focused on the continued advancement of our hydrogen powered alkaline fuel cell technology, while also seeking to accelerate revenue generation with the acquisition of complementary business lines, including our combined heat and power (CHP) PWWR Flow Stream business, which offers lower costs for in multi-residential or commercial applications,” said AFCP CEO Frank Carnevale. “With the ongoing developments and continued evolution of the company, we are grateful for the support of our shareholders and are seeking approval to reprice certain outstanding equity instruments to better align with current market conditions and afford AFCP an incremental source of future financing. We encourage all shareholders to vote on the resolution at our upcoming meeting on October 17, 2022,” he added. The proposed amendments will not be effective until shareholder approval is secured, and certain regulatory and NEO filings are completed.
Falcon Gold Corp (TSX-V:FG, OTC:FGLDF) said its shareholders have approved the Spin-Out and the company’s Arrangement Agreement with its wholly-owned subsidiary, Latamark Resources Corp at a special shareholders meeting held on September 8, 2022. Following the shareholder approval, Falcon received a final order from the Supreme Court of British Columbia approving the transaction on September 14, 2022. Pursuant to the Arrangement Agreement, the company will transfer its interest in the option agreement concerning the Esperanza gold project to Latamark in exchange for (i) Latamark issuing to the shareholders of the company, one common share in the capital of Latamark for every 5.8 common shares held in the company, (ii) Latamark issuing 5,000,000 common shares to Falcon and (iii) Latamark assuming certain liabilities incurred, exploring or maintaining the property. Falcon said it intends to proceed with the Spin-Out pending final approval of the TSX Venture Exchange, and will coordinate with its transfer agent and the TSXV regarding a record date and closing date for the distribution of the Latamark shares to Falcon shareholders.
American Manganese Inc, dba RecycLiCo Battery Materials, has announced that the TSX Venture Exchange (TSXV) has consented to the company proceeding with its change of name to RecycLiCo Battery Materials Inc. The company expects to complete the process in the coming weeks. The stock symbols on the various stock exchanges will remain unchanged following completion of the name change. On the TSXV, the symbol will remain as “AMY”; on the OTCQB, as “AMYZF”; and on the FSE, as “2AM”. The name change does not affect the rights of the company’s shareholders, neither will there be any consolidation of capital associated with it. As requested by the TSXV, American Manganese said it will seek shareholder approval for a proposed Change of Business (COB) to become a Tier 2 Industrial Issuer on the TSXV at the next annual general and special meeting. Details on the proposed COB will be circulated later.
GoviEx Uranium Inc (TSX-V:GXU, OTCQX:GVXXF) said that as part of its share purchase option plan it has granted annual incentive stock options to certain directors, officers, employees, and a consultant to purchase up to a total of 13,455,000 Class A common shares in the capital stock of the company. The stock options are exercisable at a price of $0.225 per share and will vest 25% on the date of grant and thereafter, 25% on each anniversary of the date of grant until fully vested. The options expire on September 27, 2027.
Cordoba Minerals Corp (TSX-V:CDB, OTCQB:CDBMF) has reported that at its annual general meeting of shareholders held on September 22, 2022, all directors nominated as listed in the management information circular dated August 10, 2022 were elected. Shareholders voted to set the number of Directors at five for the ensuing year. In addition, Cordoba reported shareholders voted in favour of the re-appointment of Deloitte LLP as auditors for the ensuing year. Disinterested Shareholders have also approved certain amendments to the company's stock option plan (SOP), long-term incentive plan (LTIP) and deferred share unit plan (DSU plan, and together with the SOP and LTIP, the plans).
Regency Silver Corp announced that it has entered into an agreement to option a 100% undivided interest in the Oso Blanco claims located in the state of Sonora in Mexico. The Oso Blanco claims cover an area of approximately 5,650 hectares and are located contiguous to the company’s flagship Dios Padre project, the explorer said. In order to exercise the option, the company said it must pay a total sum of US$500,000 over five years, pay back taxes and mining filings currently estimated to be US$500,000 by March 31, 2023, and issue a total of 1,000,000 common shares over 36 months. Regency Silver must also pay a US$1,000,000 bonus upon a NI 43-101 resource being published, which estimates the area of mutual interest contains a minimum of 70 million silver equivalent ounces, or 1 million gold ounces or an equivalent value in precious or base metals, in the measured or indicated categories.
Givex (TSX:GIVX, OTCQX:GIVXF) Information Technology Group Ltd said its Hong Kong office continues to grow with the recent signing of agreements with multi-unit restaurant chains to utilize its industry-leading gift card program, as well as its Customer WebSuite (CWS) to sell digital gift cards online. "Restaurant brands of all sizes and formats continue to come to Givex (Givex (TSX:GIVX, OTCQX:GIVXF), Givex (TSX:GIVX, OTCQX:GIVXF)) because of our seamless, custom integrations, customer support and flexibility," said John Sydoruk, managing director of Givex Asia in a comment. "We are thrilled to be working with prestigious, fast-growing brands and looking forward to helping increase revenue and streamline operations for our clients in Asia."
Cloud DX (TSX-V:CDX, OTCQB:CDXFF), the leading remote monitoring company, announced a new partnership with community home care provider CBI Health to offer a comprehensive home care service to Canadians. The innovative partnership enables patients to go home sooner and more safely after surgery and other complex health presentations, helping alleviate occupancy pressure on Canadian hospitals, Cloud DX said. It said the partners' first contract together is the Critical Illness (CI) benefit with insurer Equitable Life of Canada, which, as previously announced, offers Cloud DX Remote Monitoring free of charge to all approved CI claimants. This Cloud DX offering will now expand to include 24/7 monitoring with CBI's National Client Service Center, offering Equitable clients greater access to care and improved convenience. "We're excited to announce a new partnership between Cloud DX and CBI Health to expand access to quality care at home. Combining our expertise in remote and virtual care with CBI Health's professional and personal healthcare services, hospitals can discharge patients earlier with confidence," CEO and founder of Cloud DX Robert Kaul said in a statement.